How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

162 results for

Cyclic Lipopeptide

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy Full Text available with Trip Pro

Transplant 2000;25:853-9. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51. Indexing Status Subject indexing assigned by NLM MeSH Adult; Amphotericin B /administration & Antifungal Agents /administration & Antineoplastic Agents /therapeutic use; Cohort Studies; Cost-Benefit Analysis; Echinocandins; Fluconazole /administration & Humans; Leukemia, Myeloid, Acute /drug therapy; Lipopeptides (...) ; Lipoproteins /administration & Mycoses /drug therapy; Opportunistic Infections /complications /drug therapy; Peptides, Cyclic /administration & dosage /economics; dosage /economics; dosage /economics; dosage /economics; dosage /economics AccessionNumber 22006007591 Date bibliographic record published 31/10/2006 Date abstract record published 31/10/2006 NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination Copyright © 2019 University of York Homepage Options Print

2006 NHS Economic Evaluation Database.

122. Daptomycin - Skin and Skin Structure Infections & Bacteremia

Daptomycin - Skin and Skin Structure Infections & Bacteremia Common Drug Review CEDAC Meeting – July 16, 2008; CEDAC Reconsideration – September 17, 2008 Page 1 of 3 Notice of CEDAC Final Recommendation – September 24, 2008 © 2008 CADTH CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION DAPTOMYCIN (Cubicin ® – Oryx Pharmaceuticals Inc.) Description: Daptomycin is a parenteral cyclic lipopeptide antimicrobial agent with bactericidal properties against Gram positive

2008 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

123. Use of PCR-Targeted Mutagenesis To Disrupt Production of Fusaricidin-Type Antifungal Antibiotics in Paenibacillus polymyxa Full Text available with Trip Pro

of bacterial sporulation. The fusaricidins are a family of lipopeptide antibiotics consisting of a beta-hydroxy fatty acid linked to a cyclic hexapeptide. Using a reverse genetic approach based on conserved motifs of nonribosomal peptide synthetases, a DNA fragment that appears to encode the first two modules of the putative fusaricidin synthetase (fusA) was isolated from PKB1. To confirm the involvement of fusA in production of fusaricidins, a modified PCR targeting mutagenesis protocol was developed

2007 Applied and environmental microbiology

124. Massetolide A Biosynthesis in Pseudomonas fluorescens Full Text available with Trip Pro

Massetolide A Biosynthesis in Pseudomonas fluorescens Massetolide A is a cyclic lipopeptide (CLP) antibiotic produced by various Pseudomonas strains from diverse environments. Cloning, sequencing, site-directed mutagenesis, and complementation showed that massetolide A biosynthesis in P. fluorescens SS101 is governed by three nonribosomal peptide synthetase (NRPS) genes, designated massA, massB, and massC, spanning approximately 30 kb. Prediction of the nature and configuration of the amino

2007 Journal of bacteriology

125. Clinical Progression of Methicillin-Resistant Staphylococcus aureus Vertebral Osteomyelitis Associated with Reduced Susceptibility to Daptomycin Full Text available with Trip Pro

Clinical Progression of Methicillin-Resistant Staphylococcus aureus Vertebral Osteomyelitis Associated with Reduced Susceptibility to Daptomycin Daptomycin, a novel cyclic lipopeptide antibiotic, exhibits rapid bactericidal activity in vitro against most clinically relevant gram-positive organisms, including drug-resistant pathogens. Herein we describe a patient in whom methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin was responsible for bacteremia

2005 Journal of clinical microbiology

126. The Heat Shock Genes dnaK, dnaJ, and grpE Are Involved in Regulation of Putisolvin Biosynthesis in Pseudomonas putida PCL1445 Full Text available with Trip Pro

The Heat Shock Genes dnaK, dnaJ, and grpE Are Involved in Regulation of Putisolvin Biosynthesis in Pseudomonas putida PCL1445 Pseudomonas putida PCL1445 produces two cyclic lipopeptides, putisolvins I and II, which possess surfactant activity and play an important role in biofilm formation and degradation. In order to identify genes and traits that are involved in the regulation of putisolvin production of PCL1445, a Tn5luxAB library was generated and mutants were selected for the lack

2005 Journal of bacteriology

127. Neurotrophic peptide aldehydes: Solid phase synthesis of fellutamide B and a simplified analog Full Text available with Trip Pro

Neurotrophic peptide aldehydes: Solid phase synthesis of fellutamide B and a simplified analog A combination of solid phase and solution phase synthetic methods have been used to complete the total synthesis of the neurotrophic lipopeptide aldehyde fellutamide B (2). The beta-hydroxy aliphatic tail was prepared by regioselective reductive opening of a cyclic sulfate, and later coupled to a solid phase resin. The synthetic compound was then examined in cytotoxicity and nerve growth factor (NGF

2006 Bioorganic & medicinal chemistry letters

128. Surfactin-Triggered Small Vesicle Formation of Negatively Charged Membranes: A Novel Membrane-Lysis Mechanism Full Text available with Trip Pro

vesicle formation thus appears to be linked to severe changes in membrane curvature and could be described by a two-step action: 1), peptide insertion into membranes because of favorable van der Waals forces between the rather rigid cyclic and lipophilic part of SF and lipid chains and 2), electrostatic repulsion between like charges borne by lipid headgroups and the negatively charged SF amino acids. This might provide the basis for a novel mode of action of negatively charged lipopeptides. (...) Surfactin-Triggered Small Vesicle Formation of Negatively Charged Membranes: A Novel Membrane-Lysis Mechanism The molecular mode of action of the lipopeptide SF with zwitterionic and negatively charged model membranes has been investigated with solid-state NMR, light scattering, and electron microscopy. It has been found that this acidic lipopeptide (negatively charged) induces a strong destabilization of negatively charged micrometer-scale liposomes, leading to the formation of small

2008 Biophysical journal

129. Trichosporon Asahii. Blood-stream Infection in a non-cancer patient receiving Combination Antifungal Therapy Full Text available with Trip Pro

Webb C H CH Bedi A A eng Case Reports Journal Article Northern Ireland Ulster Med J 0417367 0041-6193 0 Antifungal Agents 0 Echinocandins 0 Lipopeptides 0 Peptides, Cyclic 7XU7A7DROE Amphotericin B F0XDI6ZL63 Caspofungin IM Accidents, Occupational Aged Agriculture Amphotericin B pharmacology therapeutic use Antifungal Agents therapeutic use Caspofungin Drug Therapy, Combination Echinocandins Fatal Outcome Humans Lipopeptides Male Multiple Organ Failure microbiology Mycoses drug therapy microbiology (...) Peptides, Cyclic pharmacology therapeutic use Sepsis microbiology Species Specificity Trichosporon drug effects isolation & purification 2006 9 13 9 0 2006 11 3 9 0 2006 9 13 9 0 ppublish 16964817 PMC1891755 J Clin Microbiol. 2003 Feb;41(2):911 12574315 J Clin Microbiol. 2004 May;42(5):2341-4 15131229 Scand J Infect Dis. 2004;36(8):564-9 15370667 J Clin Microbiol. 1998 Oct;36(10):2950-6 9738049 Eur J Clin Microbiol Infect Dis. 2002 Dec;21(12):892-6 12525928 South Med J. 2005 Sep;98(9):954-5 16217998

2006 The Ulster medical journal

130. Deferasirox, an Iron-Chelating Agent, as Salvage Therapy for Rhinocerebral Mucormycosis Full Text available with Trip Pro

NIAID NIH HHS United States R01 AI063382 AI NIAID NIH HHS United States R01 AI019990 AI NIAID NIH HHS United States Case Reports Letter 2006 09 25 United States Antimicrob Agents Chemother 0315061 0066-4804 0 Antifungal Agents 0 Benzoates 0 Echinocandins 0 Iron Chelating Agents 0 Lipopeptides 0 Peptides, Cyclic 0 Triazoles 7XU7A7DROE Amphotericin B F0XDI6ZL63 Caspofungin V8G4MOF2V9 Deferasirox IM Adult Amphotericin B therapeutic use Antifungal Agents therapeutic use Benzoates pharmacology Brain Stem (...) microbiology pathology Caspofungin Cavernous Sinus microbiology pathology Central Nervous System Fungal Infections drug therapy microbiology pathology Deferasirox Diabetic Ketoacidosis complications Drug Therapy, Combination Echinocandins Humans Iron Chelating Agents therapeutic use Lipopeptides Magnetic Resonance Imaging Male Mucormycosis drug therapy microbiology pathology Nose Diseases drug therapy microbiology Peptides, Cyclic therapeutic use Salvage Therapy Triazoles pharmacology 2006 9 27 9 0 2006 12

2006 Antimicrobial Agents and Chemotherapy

131. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. (Abstract)

Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Daptomycin (Cubicin; Cubist Pharmaceuticals, Inc., Lexington, MA) is a first-in-its-class cyclic lipopeptide approved for the treatment of patients with complicated skin and skin-structure infections due to susceptible gram-positive pathogens and recently approved for Staphylococcus aureus bloodstream infections including right-sided infective endocarditis. The clinical experience of patients

2007 American Journal of Medicine

132. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Full Text available with Trip Pro

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Daptomycin is the first available agent from a new class of antibiotics, the cyclic lipopeptides, that has activity against a broad range of gram-positive pathogens, including organisms that are resistant to methicillin, vancomycin, and other currently available agents. Daptomycin (4 mg/kg intravenously [iv] every 24 h for 7-14 days) was compared with conventional antibiotics

2004 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Controlled trial quality: uncertain

133. The importance of the development of antibiotic resistance in Staphylococcus aureus. Full Text available with Trip Pro

proportion of cases in the near future. New classes of antibiotic are urgently needed to treat infections with this growing population of multidrug-resistant S. aureus, and the recently introduced oxazolidinone linezolid and the cyclic lipopeptide daptomycin are welcome additions to the ever-narrowing range of therapies effective against this pathogen.

2006 Clinical Microbiology and Infection

134. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Full Text available with Trip Pro

The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. In the face of increasing resistance to currently available antibiotics, there is a continued interest in the development of new drugs to treat Gram-positive infections. One such agent is the cyclic lipopeptide daptomycin-licensed in the USA for treatment of Gram-positive complicated skin and skin structure infections (cSSSIs) in 2003 and currently awaiting European approval for a similar

2006 Clinical Microbiology and Infection

135. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. Full Text available with Trip Pro

Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. To test the efficacy of daptomycin, a cyclic lipopeptide antibiotic, against a methicillin-susceptible Staphylococcus aureus strain in experimental rabbit meningitis and to determine its penetration into non-inflamed and inflamed meningesOver a treatment period of 8 h, daptomycin (15 mg/kg) was significantly superior to the comparator regimen vancomycin (-4.54

2006 Journal of Antimicrobial Chemotherapy

136. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. Full Text available with Trip Pro

Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. Infection due to methicillin-resistant Staphylococcus aureus (MRSA) is increasingly common in nosocomial and community settings. Daptomycin is a cyclic lipopeptide anti-infective with activity against MRSA, approved for treatment of complicated skin and skin structure infections. Daptomycin may be useful in systemic or local treatment of chronic osteomyelitis.We measured mechanical strength of daptomycin

2006 Journal of Antimicrobial Chemotherapy

137. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Full Text available with Trip Pro

Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Daptomycin is a novel cyclic lipopeptide antibiotic that provides rapid bactericidal activity against gram-positive pathogens in vitro, including methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus, vancomycin-resistant S. aureus, penicillin-resistant Streptococcus pneumoniae, and ampicillin- and vancomycin-resistant enterococci. The United States Food and Drug

2004 Clinical Infectious Diseases

138. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. Full Text available with Trip Pro

advantages over bacteriostatic therapy in certain infections. Daptomycin, the first of the cyclic lipopeptides, shows rapid bactericidal activity against S. aureus, including strains tolerant or resistant to other agents. This review outlines the methods by which bactericidal and bacteriostatic properties are defined and tested, discusses the potential importance of bactericidal therapy in MRSA and other infections and examines the potential role of daptomycin in treatment.

2006 Journal of Antimicrobial Chemotherapy

139. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. Full Text available with Trip Pro

Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. Increasing antimicrobial resistance among bacterial pathogens has prompted attempts to develop new antimicrobial agents active against multidrug-resistant Gram-positive pathogens.To evaluate the in vitro activity of daptomycin against a worldwide collection of clinical bacterial isolates.Daptomycin is a novel cyclic lipopeptide recently approved by the United States Food and Drug Administration

2004 Journal of Antimicrobial Chemotherapy

140. Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever. Full Text available with Trip Pro

Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever. Daptomycin is the first antibacterial agent of the cyclic lipopeptides with in vitro bactericidal activity against gram-positive organisms, including vancomycin-resistant enterococci, methicillin-resistant staphylococci, and glycopeptide-resistant Staphylococcus aureus. The pharmacokinetics of daptomycin were determined in 29 adult oncology patients with neutropenic fever. Serial blood samples were drawn at 0, 0.5, 1

2008 Antimicrobial Agents and Chemotherapy

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>